Determination and Pharmacology of a New Hydroxylated Metabolite of Tamoxifen Observed in Patient Sera During Therapy for Advanced Breast Cancer

Cancer Research

Volumn 43, Issue 3, 1983, Pages 1446-1450

  Jordan, V Craig ^a   Bain, R ^a   Brown, Raymond R ^a   Gosden, Barbara ^a   Santos, M Amparo ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ESTRADIOL H 3; ESTROGEN RECEPTOR; HYDROXYTAMOXIFEN; NEW DRUG; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

2 [4 (1,2 DIPHENYLBUTENYL)PHENOXY]ETHANOL; ARTICLE; BREAST; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG COMPARISON; DRUG DETERMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE GENITAL SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHARMACOKINETICS; RAT; THERAPY; UTERUS;

ANIMALS; BIOLOGICAL ASSAY; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; FEMALE; HUMANS; RATS; TAMOXIFEN; UTERUS;

EID: 0020691322     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Adam, H. K., Douglas, E. J., and Kemp, J. V. The metabolism of tamoxifen in humans. Biochem. Pharmacol., 27: 145-147, 1979.
2. Adam, H. K., Gay, M. A., and Moore, R. H. Measurement of tamoxifen in serum by thin layer densitometry. J. Endocrinol., 84: 35-42, 1980.
3. Allen, K. E., Clark, E. R., and Jordan, V. C. Evidence for the metabolic activation of nonsteroidal antioestrogens: a study of structure-activity relationships. Br. J. Pharmacol., 71: 83-91, 1980.
4. Bain, R. R. and Jordan, V. C. Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. Biochem. Pharmacol., in press, 1982.
5. Borgna, J. L., and Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem., 256: 859-868, 1981.
6. Coezy, E., Borgna, J. L., and Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317-323, 1982.
7. Daniel, P., Gaskell, S. J., Bishop, H., Campbell, C., and Nicholson, R. I. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur. J. Cancer, 17: 1183-1189, 1981.
8. Fabian, C., Sternson, L., and Barnett, M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat. Rep., 67: 765-773, 1980.
9. Fabian, C., Tilzer, L., and Sternson, L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlated with blood levels in patients with metastatic breast cancer. Biopharm. Drug Dispos. 2: 381-390, 1981.
10. Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., Frelick, R., Desser, R., Li Calzi, N., Geggie, P., Campbell, T., Elias, E. G., Prager, D., Koontz, P., Volk, H., Dimitrov, N., Gardner, B., Lerner, H., Shibata, H. and other NSABP members. Treatment of primary breast cancer with chemotherapy and tamoxifen. N. Engl. J. Med., 305: 1-6, 1981.
11. Fromson, J. M., Pearson, S., and Bramah, S. The metabolism of tamoxifen (ICI 46,474): Part I in laboratory animals. Xenobiotica, 3: 693-709, 1973.
12. Fromson, J. M., Pearson, S., and Bramah, S. The metabolism of tamoxifen (ICI 46,474): Part II in female patients. Xenobiotica, 3: 710-713, 1973.
13. Furr, B. J. A., Patterson, J. S., Richardson, D. N., Slater, S. R., and Wakeling, A. E. Tamoxifen. In: M. E. Goldberg (ed.), Pharmacological and Biochemical Properties of Drug Substances, Vol. 2, pp. 355-399. Washington, D. C.: American Pharmaceutical Association, 1979.
14. Jordan, V. C. Pharmacology of antiestrogens. In: D. P. Rose (ed.), Endocrinology of Cancer III, pp. 129-173. Boca Raton, Fla.: CRC Press, Inc., 1982.
15. Jordan, V. C. Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res. Treat., 2: 123-138, 1982.
16. Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol., 75. 305-316, 1977.
17. Mouridsen, H., Palshof, T., Patterson, J., and Battersby, L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev., 5: 131-141, 1978.
18. Robertson, D. W., Katzenellenbogen, J. A., Hayes, J. R., and Katzenellenbogen, B. S. Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-{4[2-(dimethylamino)ethoxy]phenyl]-1-butene (Tamoxifen, Nolvadex®) having altered basicity. J. Med. Chem., 25: 167-171, 1982.